IL6 and congenital rubella syndrome: Alternative agents targeting the IL6 or IL1 pathways implicated in CRS include siltuximab (monoclonal antibody against IL6), ruxolitinib (a Janus kinase inhibitor that inhibits downstream IL6 signaling), and the IL1 receptor antagonist, anakinra.